Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 02

336P - Dual-mode near-infrared multispectral imaging system equipped with deep learning models improves the identification of cancer foci in breast cancer specimens

Date

21 Oct 2023

Session

Poster session 02

Topics

Tumour Site

Breast Cancer

Presenters

Yueping Liu

Citation

Annals of Oncology (2023) 34 (suppl_2): S278-S324. 10.1016/S0923-7534(23)01258-9

Authors

Y. Liu1, L. Zhang1, J. Liao2, M. Zhang1, Y. Liu1, D. Han1, Z. Jia1, S. Niu1, H. Bu3, J. Yao2

Author affiliations

  • 1 Department Of Pathology, The Fourth Hospital of Hebei Medical University, 050011 - Shijiazhuang/CN
  • 2 Ai Lab, Tencent, 518054 - shenzhen/CN
  • 3 Department Of Pathology, West China Hospital,Sichuan University, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 336P

Background

For surgically resected breast cancer samples, it is challenging to perform specimen sampling by visual inspection, especially when the tumor bed shrinks after neoadjuvant therapy in breast cancer.

Methods

We developed a dual-mode near-infrared multispectral imaging system (DNMIS) to obtain richer sample tissue information by acquiring reflection and transmission images covering visible to NIR-II spectrum range (400–1700 nm). Additionally, artificial intelligence (AI) was used to segment the rich multispectral data. 80 breast cancer samples were collected to verify the advantage of DNMIS in assisting pathologists to identify tumor beds.

Results

DNMIS demonstrated better tissue contrast and eliminated the interference of surgical inks on the breast tissue surface, helping pathologists find the tumor area which is easy to be overlooked with visual inspection. Statistically, AI-powered DNMIS provided a higher tumor sensitivity (95.9% vs visual inspection 88.4% and X-rays 92.8%), especially for breast samples after neoadjuvant therapy (90.3% vs visual inspection 68.6% and X-rays 81.8%).

Conclusions

We infer that DNMIS can improve the breast tumor specimen sampling work by helping pathologists avoid missing out tumor foci.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.